Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Age-related macular degeneration

This page shows the latest Age-related macular degeneration news and features for those working in and with pharma, biotech and healthcare.

Astellas to acquire Iveric Bio for approximately $5.9bn

Astellas to acquire Iveric Bio for approximately $5.9bn

to age-related macular degeneration (AMD).

Latest news

More from news
Approximately 5 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    for advanced dry Age-related Macular Degeneration (AMD). ... She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust

  • Deal Watch October 2018

    RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    treatments for age-related macular degeneration (AMD).

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD). ... Despite the uncertainty and challenges in our environment, particularly related to Brexit, we need

  • Deal Watch February 2016 Deal Watch February 2016

    company. Avalanche's preclinical and research stage gene therapy programmes are focused on a range of ophthalmic diseases, such as wet age-related macular degeneration, utilising adeno-associated virus (AAV) vectors. ... Onxeo is paying around $1.85m

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Biotech: it's a people business

    From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of ... Because of my mother, I was on the other side

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...

Quick links